R&D News | pharmaphorum

News

Armed with new survival data for Verzenio in early breast cancer, Lilly hopes to keep the drug's nose in front of a fast-growing rival from Novartis.

News

An attempt by the HHS to oust Susan Monarez as director of the CDC has run into a snag – she is refusing to step down.

News

Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines.

News

Hit by the loss of a partnership with Roche's Genentech unit last year, Norway's Nykode has narrowed its R&D focus.

News

Regeneron could be just a few months away from filing for a myasthenia gravis drug that can be dosed just once every three months.

News

Eli Lilly has reported the results of a third phase 3 trial of oral weight-loss therapy orforglipron, clearing the way for filings before year-end.